Retatrutide, a innovative dual-acting glucose-regulated incretin mimetic, represents a significant leap in peptide therapeutics for the treatment of type 2 diabetic conditions and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide integrates the actions of a GLP-1 receptor stimulant and a GIP receptor stimulant, off